TD Cowen lowered the firm’s price target on Hims & Hers to $23 from $25 and keeps a Hold rating on the shares. The firm hosted an investor meeting with WW management, who remain constructive on the weight-loss category, supported by continued momentum in GLP-1 medications. The company is actively investing to increase awareness of the refreshed Weight Watchers brand and to scale its evolving product portfolio.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Buy Rating on Hims & Hers: Undervalued Growth Leveraging Novo Nordisk GLP-1 Partnership and Scale Advantages
- HIMS Stock Slides after Wegovy Subscription Launch; BofA Sees 31% Drop in GLP-1 Franchise
- Private Markets: OpenAI raises additional $10B funding
- Hims & Hers GLP-1 subscription fee slightly higher than expected, says BofA
- Hims & Hers announces availability of Novo Nordisk’s GLP-1 medications